NKG2D (Natural Killer Group 2, Member D) Ligand Expression and Ameloblastoma Recurrence: a Retrospective Immunohistological Pilot Study

Overview

Journal BMC Oral Health

Publisher Biomed Central

Specialty Dentistry

Date 2024 Sep 17

PMID 39289711

Authors

Mee-Seon Kim

Soeun Jeon

Hyeon Jeong Lee

Hyun-Su Ri

Ah-Reum Cho

Eun Ji Park

Jin Song Yeo

Jae-Han Kim

Jiyoun Lee

Affiliations

Soon will be listed here.

Abstract

Background/purpose: This retrospective immunohistological pilot study aimed to investigate the influence of natural killer group 2, member D (NKG2D) ligand expression on ameloblastoma recurrence after surgical resection. It also aimed to elucidate additional clinical factors that could serve as predictors of ameloblastoma recurrence.

Materials And Methods: This study included 96 patients who were histologically diagnosed with ameloblastoma after surgical resection. The expression of NKG2D ligands, including UL16-binding proteins (ULBPs) 1-3 and major histocompatibility complex class I chain-related molecule (MIC) A/B, was evaluated in formalin-fixed paraffin-embedded tumor tissues via immunohistochemistry assays. Furthermore, the patients' electronic medical records were reviewed. Multivariate Cox regression analysis was conducted, and data were expressed as adjusted hazard ratios [HRs] with 95% confidence intervals [95% CIs].

Results: Multivariate analysis revealed that recurrent tumors (ref.: primary; adjusted HR [95% CI]: 2.780 [1.136, 6.803], p = 0.025) and positive MICA/B expression (ref.: negative; adjusted HR [95% CI]: 0.223 [0.050, 0.989], p = 0.048) independently affected recurrence-free survival in ameloblastoma.

Conclusion: This study identified recurrent cases and loss of MICA/B expression as independent predictors of early ameloblastoma recurrence following surgical resection. The findings suggest that decreased MICA/B expression might undermine NKG2D-mediated tumor immunosurveillance, thereby influencing early recurrence.

References

Yap A, Lopez-Olivo M, Dubowitz J, Hiller J, Riedel B . Anesthetic technique and cancer outcomes: a meta-analysis of total intravenous versus volatile anesthesia. Can J Anaesth. 2019; 66(5):546-561. DOI: 10.1007/s12630-019-01330-x. View

Laborde A, Nicot R, Wojcik T, Ferri J, Raoul G . Ameloblastoma of the jaws: Management and recurrence rate. Eur Ann Otorhinolaryngol Head Neck Dis. 2016; 134(1):7-11. DOI: 10.1016/j.anorl.2016.09.004. View

McClary A, West R, McClary A, Pollack J, Fischbein N, Holsinger C . Ameloblastoma: a clinical review and trends in management. Eur Arch Otorhinolaryngol. 2015; 273(7):1649-61. DOI: 10.1007/s00405-015-3631-8. View

Malmberg K, Carlsten M, Bjorklund A, Sohlberg E, Bryceson Y, Ljunggren H . Natural killer cell-mediated immunosurveillance of human cancer. Semin Immunol. 2017; 31:20-29. DOI: 10.1016/j.smim.2017.08.002. View

Hong J, Yun P, Chung I, Myoung H, Suh J, Seo B . Long-term follow up on recurrence of 305 ameloblastoma cases. Int J Oral Maxillofac Surg. 2007; 36(4):283-8. DOI: 10.1016/j.ijom.2006.11.003. View

Au S, Li K, Choi W, Su Y . Risk factors for recurrence of ameloblastoma: a long-term follow-up retrospective study. Int J Oral Maxillofac Surg. 2019; 48(10):1300-1306. DOI: 10.1016/j.ijom.2019.04.008. View

Fedchenko N, Reifenrath J . Different approaches for interpretation and reporting of immunohistochemistry analysis results in the bone tissue - a review. Diagn Pathol. 2014; 9:221. PMC: 4260254. DOI: 10.1186/s13000-014-0221-9. View

McGilvray R, Eagle R, Watson N, Al-Attar A, Ball G, Jafferji I . NKG2D ligand expression in human colorectal cancer reveals associations with prognosis and evidence for immunoediting. Clin Cancer Res. 2009; 15(22):6993-7002. PMC: 2778653. DOI: 10.1158/1078-0432.CCR-09-0991. View

Jeon S, Kim H, Kwon J, Baek S, Ri H, Choi H . Role of Sevoflurane on Natural Killer Group 2, Member D-Mediated Immune Response in Non-Small-Cell Lung Cancer: An In Vitro Study. Med Sci Monit. 2020; 26:e926395. PMC: 7648410. DOI: 10.12659/MSM.926395. View

10.

Pati S, Irfan W, Jameel A, Ahmed S, Shahid R . Obesity and Cancer: A Current Overview of Epidemiology, Pathogenesis, Outcomes, and Management. Cancers (Basel). 2023; 15(2). PMC: 9857053. DOI: 10.3390/cancers15020485. View

11.

da Silva Y, Tartaroti N, Sendyk D, Deboni M, Naclerio-Homem M . Is conservative surgery a better choice for the solid/multicystic ameloblastoma than radical surgery regarding recurrence? A systematic review. Oral Maxillofac Surg. 2018; 22(4):349-356. DOI: 10.1007/s10006-018-0715-9. View

12.

Soltanizadeh S, Degett T, Gogenur I . Outcomes of cancer surgery after inhalational and intravenous anesthesia: A systematic review. J Clin Anesth. 2017; 42:19-25. DOI: 10.1016/j.jclinane.2017.08.001. View

13.

Backstrom E, Kristensson K, Ljunggren H . Activation of natural killer cells: underlying molecular mechanisms revealed. Scand J Immunol. 2004; 60(1-2):14-22. DOI: 10.1111/j.0300-9475.2004.01475.x. View

14.

Sun B, Yang D, Dai H, Liu X, Jia R, Cui X . Eradication of Hepatocellular Carcinoma by NKG2D-Based CAR-T Cells. Cancer Immunol Res. 2019; 7(11):1813-1823. DOI: 10.1158/2326-6066.CIR-19-0026. View

15.

Moretta L, Locatelli F, Pende D, Marcenaro E, Mingari M, Moretta A . Killer Ig-like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation. Blood. 2010; 117(3):764-71. DOI: 10.1182/blood-2010-08-264085. View

16.

Vittinghoff E, McCulloch C . Relaxing the rule of ten events per variable in logistic and Cox regression. Am J Epidemiol. 2006; 165(6):710-8. DOI: 10.1093/aje/kwk052. View

17.

Hresko A, Palyvoda R, Burtyn O, Chepurnyi Y, Kopchak A, Helder M . Recurrent Ameloblastoma: Clinical Manifestation and Disease-Free Survival Rate. J Oncol. 2022; 2022:2148086. PMC: 9381261. DOI: 10.1155/2022/2148086. View

18.

de Kruijf E, Sajet A, van Nes J, Putter H, Smit V, Eagle R . NKG2D ligand tumor expression and association with clinical outcome in early breast cancer patients: an observational study. BMC Cancer. 2012; 12:24. PMC: 3292504. DOI: 10.1186/1471-2407-12-24. View

19.

Tan G, Spillane K, Maher J . The Role and Regulation of the NKG2D/NKG2D Ligand System in Cancer. Biology (Basel). 2023; 12(8). PMC: 10452210. DOI: 10.3390/biology12081079. View

20.

Kim H, Jeon S, Lee H, Bae J, Ri H, Hong J . Effects of sevoflurane on metalloproteinase and natural killer group 2, member D (NKG2D) ligand expression and natural killer cell-mediated cytotoxicity in breast cancer: an in vitro study. Korean J Anesthesiol. 2023; 76(6):627-639. PMC: 10718625. DOI: 10.4097/kja.23323. View